Characterisation of the calcitonin gene-related peptide receptor antagonists ubrogepant and atogepant in human isolated coronary, cerebral and middle meningeal arteries
Open Access
- 1 November 2019
- journal article
- research article
- Published by SAGE Publications in Cephalalgia
- Vol. 40 (4), 357-366
- https://doi.org/10.1177/0333102419884943
Abstract
Migraine has been associated with a dysfunctional activation of the trigeminovascular system. Calcitonin gene-related peptide, a neuropeptide released from the trigeminal nerve fibres, has an important role in the pathophysiology of migraine and is a current therapeutic target for migraine treatment. We examined the effects of two novel calcitonin gene-related peptide receptor antagonists, ubrogepant and atogepant, on the relaxations induced by α calcitonin gene-related peptide in human isolated middle meningeal, cerebral and coronary arteries. Furthermore, the contractile responses to atogepant and ubrogepant per se were studied and compared to the responses elicited by zolmitriptan in proximal and distal human coronary arteries. In intracranial arteries, both blockers antagonized the calcitonin gene-related peptide-induced relaxations more potently when compared to the inhibition observed in distal human coronary arteries, with atogepant showing a higher potency. When analysing their antagonistic profile in HCA, ubrogepant showed a competitive antagonist profile, while atogepant showed a non-competitive one. Neither of the gepants had vasoconstrictor effect at any of the concentrations studied in human coronary arteries, whereas zolmitriptan elicited concentration-dependent contractions. ubrogepant and atogepant differentially inhibit the calcitonin gene-related peptide-dependent vasodilatory responses in intracranial arteries when compared to distal human coronary arteries. Also, both gepants are devoid of vasoconstrictive properties in human coronary arteries.Keywords
Funding Information
- Consejo Nacional de Ciencia y Tecnología (fellowship No. 409865)
- Allergan plc.
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek (Vidi grant 917.113.349)
This publication has 45 references indexed in Scilit:
- Intracranial and extracranial arteries in migraineThe Lancet Neurology, 2013
- Characterization of the Calcitonin Gene-Related Peptide Receptor Antagonist Telcagepant (MK-0974) in Human Isolated Coronary ArteriesThe Journal of pharmacology and experimental therapeutics, 2010
- Effect of the calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant in human cranial arteriesCephalalgia, 2010
- Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraineNeurology, 2008
- Determining the Potency and Molecular Mechanism of Action of Insurmountable AntagonistsThe Journal of pharmacology and experimental therapeutics, 2006
- Characterisation of CGRP receptors in the human isolated middle meningeal arteryLife Sciences, 2006
- Neurobiology in primary headachesBrain Research Reviews, 2005
- The CGRP-Antagonist, BIBN4096BS Does not Affect Cerebral or Systemic Haemodynamics in Healthy VolunteersCephalalgia, 2005
- Vasoactive peptide release in the extracerebral circulation of humans during migraine headacheAnnals of Neurology, 1990
- Elevation of beta-adrenergic receptor density in human lymphocytes after propranolol administration.JCI Insight, 1980